Scarica l'app Stockscreener
42.12
3.55%
1.445
Dopo l'orario di chiusura:
42.15
0.025
+0.06%
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport Therapeutics Inc (RAPP) Valuation: PE, PB & Fair Value Analysis - TradingKey
William Blair initiates Rapport Therapeutics stock with outperform rating - Investing.com
William Blair initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Rapport Therapeutics Market Sentiment - Benzinga España
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
RAPP|Rapport Therapeutics Inc|Price:40.680|Chg%:-0.700 - TradingKey
RAPP|Rapport Therapeutics Inc|Price:41.780|Chg%:+1.100 - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RAPP|Rapport Therapeutics Inc|Price:42.150|Chg%:+1.470 - TradingKey
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rapport Therapeutics Inc (RAPP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to earnings forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Price to sales forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
Responsive Playbooks and the RAPP Inflection - Stock Traders Daily
Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $58 - Moomoo
Enterprise value to EBITDA forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF) - The Globe and Mail
Rapport Therapeutics (RAPP) Q1 2026 earnings summary - Quartr
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating - Moomoo
RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics - TipRanks
RAPP Reiterates by BTIG -- Price Target Maintained at $65.00 - GuruFocus
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com - Investing.com Nigeria
Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock - Investing.com
Rapport Therapeutics (RAPP) Slips 1.85%, Approaching Key Support at $38.66Bullish Percent Index - dars.gov.et
Enterprise value to revenue forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Enterprise value to EBIT forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? - Yahoo Finance
Rapport Therapeutics (RAPP) Stifel 2026 Virtual CNS Forum Summary - Quartr
Rapport Therapeutics (RAPP) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Rapport Therapeutics (RAPP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate - Moomoo
How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - simplywall.st
RAPPRapport Therapeutics Inc Short Interest - Finviz
Rapport Therapeutics Hits New 52-Week High of $43.65 - MarketsMojo
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap - GuruFocus
Understanding the Setup: (RAPP) and Scalable Risk - Stock Traders Daily
Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades - Stock Titan
Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans - Stock Titan
Rapport Therapeutics (RAPP) Declines 2.3% as Shares Approach Key SupportETF Liquidity - dars.gov.et
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com - Investing.com Nigeria
Rapport Therapeutics stock hits all-time high at 42.36 USD - Investing.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2500 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark - marketscreener.com
Rapport Therapeutics (RAPP) Stifel 2025 Healthcare Conference Summary - Quartr
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP) - TradingView
RAPP Forecast — Price Target — Prediction for 2027 - TradingView
RAPP Initiated Coverage by Leerink Partners -- Rating set to Out - GuruFocus
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target - marketscreener.com
Leerink initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
The Technical Signals Behind (RAPP) That Institutions Follow - Stock Traders Daily
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):